About the program
Duchenne muscular dystrophy (DMD) is a rare genetic disease characterized by progressive muscle degeneration and weakness caused by mutations in the gene that codifies the protein dystrophin. It usually emerges in early childhood and significantly impacts life expectancy. Achieving an accurate and early diagnosis is crucial for patients as it allows for earlier intervention, genetic counseling, and ultimately improved outcomes. Although DMD remains a progressive incurable disease, life expectancy has increased in the last few decades thanks to the implementation of multidisciplinary patient-centered care and improving treatment for cardiopulmonary dysfunction.
This expert-led program is designed to empower HCPs working in multidisciplinary teams by equipping them with key knowledge and skills to enhance diagnosis, treatment, and management of patients with DMD.
Learning objectives
Following completion of this independent educational program, you will be able to:
- Recognize potential signs and symptoms of DMD to avoid delays in referrals and treatment onset
- Explain multidisciplinary team approaches, including potential challenges, for optimizing patient management and improving quality of life
- Discuss recommendations to refine DMD treatment strategies, continuity of care, and patient monitoring
Target audience
This program is aimed at an international audience of pediatric neurologists, primary care physicians, pediatricians, geneticists, genetic counselors, neuromuscular specialists, nurse practitioners, pulmonologists, cardiologists, endocrinologists, orthopedists and physical therapists that make up the multidisciplinary care teams for DMD throughout the patient journey.
Planning Committee
In addition to the expert faculty Springer Healthcare IME planners and staff include Rachel Goddard, Alba Ruzafa and James Hutton. The Planning Committee have no financial relationships to disclose.
All relevant financial relationships of the Faculty have been mitigated.
